Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
FBLG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $4.41
Previous CloseN/A
Volume56.64K
Average Volume (3M)488.86K
Market Cap
$25.34M
Enterprise Value$25.97M
Total Cash (Recent Filing)$8.85M
Total Debt (Recent Filing)$10.78M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 18, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding41,889,140
10 Day Avg. Volume419,628
30 Day Avg. Volume488,861
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)24.04
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue46.88
Enterprise Value/Gross Profit365.77
Enterprise Value/Ebitda-2.07
Forecast
1Y Price Target
$10.00Price Target Upside1512.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market PotentialChronic wound care represents a sizable market with $28B in healthcare spending with nearly 2 million patients experiencing venous leg ulcers and diabetic foot ulcers annually.
Regenerative MedicineFibroblasts have significant potential in regenerative medicine as they share a host of overlapping properties with stem cells, making them a potentially less expensive and more accessible cell therapy for patients.
Research And DevelopmentThe company has completed a $5M financing tranche to support research and development and clinical trials, which is a positive step for future growth.
Bears Say
Clinical Trial TimelinesThe company plans to complete preclinical IND-enabling work for the fibroblast treatment of psoriasis by the end of 2025.
ValuationThe price target has been adjusted from $12 to $10 per share, indicating a change in valuation expectations.
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.53 and its highest was $4.41 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $25.34M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 81 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Jul 31, 2025. The company reported -$0.12 earnings per share for the quarter, the consensus estimate of -$0.12 by $0.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 41,889,140 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.12 in its last earnings report, expectations of -$0.12. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at 0.
FibroBiologics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1512.90% Upside)
$10.00 (1512.90% Upside)
Blogger Sentiment
Bullish
FBLG Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.25%
12-Months-Change
Fundamentals
Return on Equity
-559.73%
Trailing 12-Months
Asset Growth
56.05%
Trailing 12-Months
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$10.00
▲(1512.90% Upside)
Technical Analysis
Dyadic International
―
Forte Biosciences
―
Reviva Pharmaceuticals Holdings
―
Connect Biopharma Holdings
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
14.18% Insiders
5.19% Mutual Funds
1.95% Other Institutional Investors
75.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---